Thromb Haemost 2005; 94(02): 454-459
DOI: 10.1160/TH05-03-0206
New Technologies and DiagnosticTools
Schattauer GmbH

Coagulation factor XIII-A

A flow cytometric intracellular marker in the classification of acute myeloid leukemias
János Kappelmayer
1   Departments of Clinical Biochemistry and Molecular Pathology, University of Debrecen, Debrecen, Hungary
,
Ágnes Simon
1   Departments of Clinical Biochemistry and Molecular Pathology, University of Debrecen, Debrecen, Hungary
,
Éva Katona
2   Departments of Clinical Research Center, University of Debrecen, Debrecen, Hungary
,
Attila Szanto
3   Department of Biochemistry and Molecular Biology, University of Debrecen, Debrecen, Hungary
,
László Nagy
3   Department of Biochemistry and Molecular Biology, University of Debrecen, Debrecen, Hungary
,
Attila Kiss
4   2nd Department of Medicine, University of Debrecen, Debrecen, Hungary
,
Csongor Kiss
5   Department of Pediatrics, Medical and Health Science Centre, University of Debrecen, Debrecen, Hungary
,
László Muszbek
1   Departments of Clinical Biochemistry and Molecular Pathology, University of Debrecen, Debrecen, Hungary
2   Departments of Clinical Research Center, University of Debrecen, Debrecen, Hungary
› Author Affiliations

Financial support: The study was supported by the following OTKA grants: TS 044796, 043086, T 038307 and T 049392.
Further Information

Publication History

Received: 25 March 2005

Accepted after major revision: 04 June 2005

Publication Date:
05 December 2017 (online)

Preview

Summary

The association of coagulation factors with leukocytes have been demonstrated in several previous studies. This study was designed to study the sensitivity and specificity of factor XIII subunit A (FXIII-A) labelling in cultured myeloblastic and monoblastic cell lines and to investigate the intracytoplasmic expression of FXIII-A in de novo acute myeloid leukemia (AML) samples. Myeloblastic and a monoblastic cell lines were cultured and investigated for lineage specific maturation markers and FXIII-A expression. Furthermore, FXIII-A expression was investigated in 12 normal samples (7 bone marrow and 5 peripheral blood), 86 de novo AML samples and 6 chronic myelomonocytic leukemia (CMML) samples. In the monoblastic MonoMac6 cell line the appearance of FXIII-A preceded that of CD14 while it remained negative in the myeloblastic PLB-985 cell line throughout its maturation period. Among the AML samples the average frequency of FXIII-A positive cells in myeloblastic leukemia samples was below 10%,while in M4 and M5AML samples it was above 50% and was significantly higher than the generally used CD14 marker (p < 0.0001). In the AML M4 and M5 cases, FXIII-A proved sensitive for the identification of monoblasts.FXIII-A can be considered as a reliable intracytoplasmic marker for the monocytic and megakaryocytic series and its presence is highly predictive for mono- and megakaryocytic AML and for CMML